UnknownPhase 4NCT03677557

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Studying Primary immunodeficiency

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ottawa Hospital Research Institute
Principal Investigator
Juthaporn Cowan, MD, PhD, FRCPC
The Ottawa Hospital
Intervention
16,5% Cutaquig(drug)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2021

Study locations (1)

Collaborators

Octapharma

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03677557 on ClinicalTrials.gov

Other trials for Primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Primary immunodeficiency →

← Back to all trials